CE / CME
Physicians: Maximum of 0.25 AMA PRA Category 1 Credit™
Nurses: 0.25 Nursing contact hour
Released: February 26, 2020
Expiration: February 25, 2021
Share
Martin J. Abrahamson, MD, FACP
Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Department of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Zachary T. Bloomgarden, MD, MACE
Clinical Professor
Division of Endocrinology
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
Linda R. Duska, MD, MPH
Professor, Gynecologic Oncology
Vice Chair for Research
Department of Obstetrics and Gynecology
Associate Dean for Clinical Research
University of Virginia School of Medicine
Charlottesville, Virginia
Anne Peters, MD
Director
USC Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine of USC
University of Southern California
Los Angeles, California
Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida
Lauren Prescott, MD
Assistant Professor, Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Ritu Salani, MD, MBA
Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California
Renata R. Urban, MD
Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
University of Washington School of Medicine
University of Washington Medical Center
Fred Hutchinson/Seattle Cancer Care Alliance
Seattle, Washington
Shannon N. Westin, MD, MPH
Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Robert S. Zimmerman, MD
Vice Chairman
Director, Cleveland Clinic Diabetes Center
Department of Endocrinology
Cleveland Clinic
Cleveland, Ohio
Novo Nordisk Inc
This program is intended for primary care providers, physicians, nurse practitioners, physician assistants, and the patients with diabetes under their care.
Upon completion of this activity, participants should be able to:
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Primary Author
Martin J. Abrahamson, MD, FACP
Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Department of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Martin J. Abrahamson, MD, FACP, has disclosed that he has received consulting fees from AstraZeneca and Novo Nordisk.
Zachary T. Bloomgarden, MD, MACE
Clinical Professor
Division of Endocrinology
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
Zachary T. Bloomgarden, MD, MACE, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Merck, Novartis, and Sanofi and has ownership interest in Humana, Johnson & Johnson, and Novartis.
Linda R. Duska, MD, MPH
Professor, Gynecologic Oncology
Vice Chair for Research
Department of Obstetrics and Gynecology
Associate Dean for Clinical Research
University of Virginia School of Medicine
Charlottesville, Virginia
Linda R. Duska, MD, MPH, has no relevant financial relationships to disclose.
Anne Peters, MD
Director
USC Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine of USC
University of Southern California
Los Angeles, California
Anne Peters, MD, has disclosed that she has received consulting fees from Abbott Diabetes Care, Boehringer Ingelheim, Lilly, Livongo, MannKind, Merck, Novo Nordisk, Pendulum Therapeutics, and Sanofi; has received funds for research support from Dexcom and vTv Therapeutics; and has ownership interest in Livongo, Mellitus Health, Omada Health, Pendulum Therapeutics, and Stability Health.
Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida
Richard E. Pratley, MD, has disclosed that he has received funds for research support paid to his institution from Lexicon, Ligand, Lilly, Merck, Novo Nordisk, and Sanofi; consulting fees from GlaxoSmithKline, Janssen, Lilly, Merck, Novo Nordisk, and Sanofi; and fees for non-CME/CE services paid to his institution from Novo Nordisk.
Lauren Prescott, MD
Assistant Professor, Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Lauren Prescott, MD, has no relevant financial relationships to disclose.
Ritu Salani, MD, MBA
Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California
Ritu Salani, MD, MBA: consultant/advisor/speaker: GSK, Merck, Regeneron, Seagen.
Renata R. Urban, MD
Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
University of Washington School of Medicine
University of Washington Medical Center
Fred Hutchinson/Seattle Cancer Care Alliance
Seattle, Washington
Renata R. Urban, MD, has no financial relationships to disclose.
Shannon N. Westin, MD, MPH
Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Robert S. Zimmerman, MD
Vice Chairman
Director, Cleveland Clinic Diabetes Center
Department of Endocrinology
Cleveland Clinic
Cleveland, Ohio
Robert Zimmerman, MD, has disclosed that he has received consulting fees from Novo Nordisk; fees for non-CME/CE services from LifeScan and Merck; and funds for research support from Bayer, Merck, and Novo Nordisk.
Staff
Zachary Schwartz, MSc, ELS
Scientific Director
Zachary Schwartz, MSc, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD
Associate Director, Scientific Services
Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 26, 2020, through February 25, 2021:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Program Medium
This program has been made available online.
The goal of this ClinicalImpact curriculum is to improve the competence of primary care physicians, nurse practitioners, physician assistants, and other members of the healthcare team in managing type 2 diabetes.